Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer

Yan, Ann-Rong; Samarawickrema, Indira; Naunton, Mark; Peterson, Gregory M.; Yip, Desmond; Rosa, Salvatore De; Mortazavi, Reza

doi:10.3390/healthcare9060778

Cited by 7 publications

(6 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prediction models used for VTE risk assessment of cancer patients include the Khorana score, PROTECHT score, COMPASS-CAT score, and CONKO score. These models have been developed and validated in patients with ambulatory lung cancer[ 16 ]. Khorana score is currently the most validated chemotherapy-related VTE risk assessment model, which is a reliable model based on five clinical and laboratory parameters.…”

Section: Discussionmentioning

confidence: 99%

Arteriovenous thrombotic events in a patient with advanced lung cancer following bevacizumab plus chemotherapy: A case report

Kong¹,

Xu²,

Liu³

2022

WJCC

View full text Add to dashboard Cite

BACKGROUND In driver gene-negative non-small cell lung cancer patients who relapse following radical resection, combination chemotherapy using bevacizumab and platinum-based dual drugs is known to increase both progression-free and overall survival. Treatment initially includes bevacizumab, and if patients are able to tolerate it, bevacizumab can continue to be utilized until disease progression. Bevacizumab is a recombinant humanized monoclonal neutralizing antibody that acts against vascular endothelial growth factor (VEGF). Various anti-VEGF monoclonal antibodies, such as bevacizumab, can increase the risk of arterial thromboembolism. Current data indicate that VEGF-targeted treatment does not significantly increase the risk of venous thromboembolism events, except for bevacizumab. CASE SUMMARY A 55-year-old man underwent radical resection for cancer of the right lung. Six months following surgery, multiple metastases were observed in his left lung. Subsequently, six cycles of bevacizumab combined with pemetrexed/carboplatin chemotherapy was given. Efficacy evaluation continued to be partial relief according to RECIST 1.1 standards, and no noticeable adverse reactions were noted. After three cycles of maintenance therapy using a combination of bevacizumab and pemetrexed, the patient developed dizziness and dyspnea. The patient was diagnosed with acute cerebral infarction and pulmonary embolism following head magnetic resonance imaging, computed tomography (CT) angiography, and chest enhanced CT. Although the patient received low-molecular-weight heparin anticoagulation and other treatment, the patient eventually died of respiratory failure 1 mo later. This case report may offer some insight into fatal arteriovenous embolism, which has not been previously reported. CONCLUSION Bevacizumab combined with chemotherapy may also increase the risk of arteriovenous thromboembolism. Accordingly, patients who receive angiogenesis inhibitor therapy should be carefully selected. Furthermore, close monitoring and timely intervention are necessary in order to reduce the risk of such toxicities.

show abstract

Section: Discussionmentioning

confidence: 99%

Arteriovenous thrombotic events in a patient with advanced lung cancer following bevacizumab plus chemotherapy: A case report

Kong¹,

Xu²,

Liu³

2022

WJCC

View full text Add to dashboard Cite

show abstract

“…15 The COMPASS-CAT Score had an improved sensitivity of 83% but a worsened specificity of 51% (95% CIs were not reported). 22 In our recent brief review, we identified some risk prediction models for VTE in ambulatory patients with lung cancer; 23 however, their performance is still largely unclear. 10 11 15 22 24 It is still uncertain how many VTE prediction models in total are available and which prediction model best suits the clinical purpose in terms of a reliable predictive performance in ambulatory patients with lung cancer.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol

et al. 2021

Self Cite

View full text Add to dashboard Cite

IntroductionVenous thromboembolism (VTE) is a common complication in patients with cancer and has a determining role in the disease prognosis. The risk is significantly increased with certain types of cancer, such as lung cancer. Partly due to difficulties in managing haemorrhage in outpatient settings, anticoagulant prophylaxis is only recommended for ambulatory patients at high risk of VTE. This requires a precise VTE risk assessment in individual patients. Although VTE risk assessment models have been developed and updated in recent years, there are conflicting reports on the effectiveness of such risk prediction models in patient management. The aim of this systematic review is to gain a better understanding of the available VTE risk assessment tools for ambulatory patients with lung cancer and compare their predictive performance.Methods and analysisA systematic review will be conducted using MEDLINE, Cochrane Library, CINAHL, Scopus and Web of Science databases from inception to 30 September 2021, to identify all reports published in English describing VTE risk prediction models which have included adult ambulatory patients with primary lung cancer for model development and/or validation. Two independent reviewers will conduct article screening, study selection, data extraction and quality assessment of the primary studies. Any disagreements will be referred to a third researcher to resolve. The included studies will be assessed for risk of bias and applicability. The Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies will be used for data extraction and appraisal. Data from similar studies will be used for meta-analysis to determine the incidence of VTE and the performance of the risk models.Ethics and disseminationEthics approval is not required. We will disseminate the results in a peer-reviewed journal.PROSPERO registration numberCRD42021245907.

show abstract

“…Previous studies have confirmed that VTE is a risk factor for many cancers, such as lung cancer [ 4 ], pancreatic cancer, and gastroesophageal cancer [ 5 ]. VTE is the most common complication in cancer patients and the second leading cause of death in cancer patients [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Machine learning predicts cancer-associated venous thromboembolism using clinically available variables in gastric cancer patients

Lei

et al. 2023

Heliyon

View full text Add to dashboard Cite

Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer

Cited by 7 publications

References 67 publications

Arteriovenous thrombotic events in a patient with advanced lung cancer following bevacizumab plus chemotherapy: A case report

Arteriovenous thrombotic events in a patient with advanced lung cancer following bevacizumab plus chemotherapy: A case report

Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol

Machine learning predicts cancer-associated venous thromboembolism using clinically available variables in gastric cancer patients

Contact Info

Product

Resources

About